Shares of AstraZeneca PLC (STO:AZN) last traded at 772.5, representing a move of 0.95%, or 7.3 per share, on volume of 520,572 shares. After opening the trading day at 749.3, shares of AstraZeneca PLC traded in a close range. AstraZeneca PLC currently has a total float of shares and on average sees 437,429 shares exchange hands each day. The stock now has a 52-week low of 577.8 and high of 805.5.

Nasdaq Stockholm: A Nordic Nation’s Pride

Sweden is home to one of the best and most accomplished economies in the world. It is truly a pride of the European Union (EU), especially now that Great Britain has decided to leave the political organization. AstraZeneca PLC is not very concern for its investors. With the Brexit, the Swedish economy is now more than ever at a more competent position to carry out growth prospects.

Stockholm Stock Exchange or Nasdaq Stockholm

The Nasdaq Stockholm, located in Frihamnen, Stockholm, is the primary stock exchange in Sweden. It is also one of the main stock exchanges in other Nordic countries including Denmark, Finland, Iceland, and Norway.

The Nasdaq Stockholm had been established as early as 1863, making it one of the oldest stock exchange in Europe and in the world as well. Until about the first half of the calendar year 1990, trading on the Nasdaq Stockholm occurs on the floor at the Stockholm Stock Exchange Building. Electronic trading was only launched on June 1, 1990. And now it provides numerous improvements in the common work for AstraZeneca PLC.

Nasdaq, Inc. owns the Nasdaq Stockholm since 2008. Consequently, it is part of Nasdaq Nordic, a subsidiary of Nasdaq founded in 2003. Other stock exchanges overseen by Nasdaq Nordic include the Armenia Stock Exchange or Nasdaq OMX Armenia, the Copenhagen Stock Exchange or Nasdaq Copenhagen, the Helsinki Stock Exchange or Nasdaq Helsinki, the Iceland Stock Exchange or Nasdaq Iceland, the Riga Stock Exchange or Nasdaq Baltic, and the Tallinn Stock Exchange or Nasdaq Baltic.

As of March, more than 300 companies are listed on the Nasdaq Stockholm. In totality, it has a market capitalization of roughly $1.26 trillion.

The regular trading session on the Nasdaq Stockholm begins at 9:00 a.m. and ends at 5:00 p.m.

OMX Stockholm 30 Index (OMXS30)

The OMXS30 is the benchmark Swedish index measuring the top 30 stocks on the Nasdaq Stockholm based on market capitalization. It uses the base value of 125 points, which has a base date of September 1986. The OMXS30 has numerous sectors; and the three biggest sectors include Consumer Services, Financials, and Industrials. OMXS30 guarantee the stability for AstraZeneca PLC work, as well.

The components of the OMXS30 are reviewed semi-annually in order to guarantee an accurate representation of the Swedish equity market. During rebalancing periods, it is only normal for the OMXS30 to forego some components and welcome new ones. It always depends on the companies’ liquidity, market capitalization, and several other factors.

The OMXS30 has touched its all-time low of 98.86 points in November 1987. The substantial losses are widely attributed to the Black Monday, an occurrence that had shaken the global equity market. It all began when stocks on the Stock Exchange of Hong Kong (SEHK) had significantly declined on October 19, 1987.

Eventually, the OMXS30 was able to recoup from the dark times in global economy history. It has touched its all-time high of 1,719.93 in April 2015.

Today is the best time to enter the European equity market, particularly that of Sweden. And perhaps check some companies like AstraZeneca PLC. With low interest rates, Europe is surely an ideal place for investors to bet on through the Nasdaq Stockholm.

More notable recent AstraZeneca PLC (STO:AZN) news were published by: Nasdaq.com which released: “Statoil ASA (STO) Ex-Dividend Date Scheduled for May 16, 2018 – Nasdaq” on May 15, 2018, also with their article: “Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week (Oct. 22-26) – Benzinga” published on October 26, 2018, Bloomberg.com published: “British Doctors Lack Transparency Where Big Pharma Pays – Bloomberg” on July 03, 2018. More interesting news about AstraZeneca PLC (STO:AZN) were released by: Prnewswire.com and their article: “Amgen to terminate participation in co-development and commercialization of brodalumab – PR Newswire” published on May 22, 2015 as well as ‘s news article titled: “Wedbush: American Eagle (NYSE:AEO) Bull Case Is Priced Into The Stock – Benzinga” with publication date: August 27, 2018.

AstraZeneca PLC develops, manufactures, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, infection, gastrointestinal, and neuroscience diseases worldwide. The company has market cap of $. The Company’s marketed products comprise Arimidex, Casodex/Cosudex, Faslodex, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Imdur, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Symlin, Xigduo, and Xigduo XR for metabolic diseases. It has a 454.41 P/E ratio. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalent and Synagis for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, Vimovo1, and Zomig for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases.